AIDAN raises concerns over NPPA chairman's transfer

Demands that the NPPA be made into a statutory body to ensure the independence and integrity of the regulator

xffxcvxvx

Pratap Vikram Singh | March 1, 2018 | New Delhi


#AIDAN   #NPPA   #All India Drug Action Network   #National Pharmaceutical Pricing Authority  

All India Drug Action Network (AIDAN) has accused US-based multinational firms in healthcare for running a malicious campaign against National Pharmaceutical Pricing Authority (NPPA) and the transfer of its chairman Bhupendra Singh. The government move would adversely impact the NPPA's ongoing work against unethical profiteering by pharmaceutical companies, device makers and corporate hospitals, the AIDAN said in a statement.

According to a government notification issued on Wednesday, the appointments committee of the cabinet has transferred Singh to National Authority for Chemical Weapons Convention in the rank and pay of additional secretary.

"The NPPA under the governance of Injeti Srinivas (former chairman) and Singh showered tremendous leadership. Srinivas was transferred even before the completion of one year following the price regulation of critical cardiac and diabetes medicines through public interest of the DPCO. During his term, Singh has taken many positive steps to ensure affordability of medicines and medical devices that discomforted the industry," the AIDAN, a non-governmental organisation working towards increasing access and rational use of essential medicines, said. 

Notably, the NPPA undertook landmark price control of stents and knee implants. There was greater accountability to the public because of increased transparency and responsiveness to grievances of patients and the industry.

The NPPA, the AIDAN said, also saw unprecedented success in the courts with its stands vindicated by favourable judgments passed by the supreme court and high courts in most cases.

Of late, the NPPA took a proactive role in initiating monitoring of high margins charged by private hospitals in an effort to curb unethical profiteering.

"We fear that Singh's transfer in total disregard to the public interest is due to the pressure from the industry and corporate hospital lobby," the AIDAN said.

The pharmaceutical industry has long sought to undermine and weaken the NPPA in order to enable uninhibited profiteering and circumvention of the law. The recent price revise of coronary stents angered the US-based MNCs which ran a malicious campaign against the regulatory authority, the AIDAN said. 

"The final precipitating factor, we believe, was the report analysing bills of four patients and which exposed the gross overcharging and misconduct of private hospitals. In this same report, the NPPA appealed for policy intervention to correct the injustice towards patients as it had reached the limits of its mandate," the non-governmental organisation said.  

The AIDAN urged the government to reconsider its decision and allow Singh to complete his three year term at the NPPA. It also demanded that the NPPA be made into a statutory body along with fixed term periods for the chairman and leadership to ensure the independence and integrity of the regulator.

Comments

 

Other News

COVID-19 demobilisation: Lessons for public governance

Demobilization, like its predecessor – demonetization, is another decision gone bad in implementation.  In both instances a careful public administrative action through its governance systems could have saved the magnitude of impact particularly on the most vulnerable sections of the society. Th

Don’t fear Corona, fight it

In a bid to break the “chain of transmission” of the deadly Covid-19, India, a country with more than 1.3 billion population, observed a voluntary ‘Janata Curfew’ on March 22. This has been followed by a 21-day, nationwide lockdown from March 24. Prime minister Narendra Modi also re

Sci-Tech Empowered Committee set up for COVID-19

To take speedy decisions on research and development for Sars-Cov-2 virus and COVID-19, the government has constituted a Science and Technology Empowered Committee. The committee, set up on March 29 and chaired by Niti Aayog member, professor Vinod Paul and professor K Vijay Raghavan, princi

Covid-19 and real estate: This could be last straw that broke camel’s back

Covid-19 may turn out to be the last straw that broke the camel’s back so far as the real estate sector is concerned. It broke out at a time when pundits were estimating the GDP to be hovering around 2.5% with unprecedent levels of unemployment. This itself was a good indicator that the real estate s

India ramps efforts as COVID-19 cases rise

As COVID -19 cases continue to rise amid a 21-day lockdown, the centre and the states are proactively taking measures to provide aid to the underprivileged and the needy during this unprecedented situation.         By Sunday morning, India had registered 27

Diplomacy in the time of Covid-19

In the thick of battle with the deadly coronavirus, India on March announced a 21-day lockdown till April 14 in its bid to control the spread of virus which has so far led to 10 people’s death and over 600 others falling sick across the country. As per experts, India, which is in the second stage of



Archives

Current Issue

Opinion

Facebook    Twitter    Google Plus    Linkedin    Subscribe Newsletter

Twitter